Squadron Capital LLC sold $525K of KIDS

Squadron Capital LLC sold 22,500 shares of ORTHOPEDIATRICS CORP (KIDS) at $23.35 ($0.53M total) on 2026-09-02. Filed jointly with Squadron Capital Holdings LLC (10% owner).

Original reporting
SEC EDGAR · Squadron Capital LLC, Squadron Capital Holdings LLC
Published Sep 4, 2026, 8:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KIDS
Bearish
medium confidence
Mentioned
$KIDS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KIDSBearishLow
01

Why it matters

The disclosed sale is modest in size and unlikely to move the stock significantly, but it adds a data point for tracking insider activity.

02

Market read

Provides a fresh insider transaction for KIDS; modest relevance for short‑term traders.

03

What to watch

Potential tax‑loss harvesting or fund liquidity needs may have driven the sale.

Relevance 5/10Novelty 6/10Timing: post‑market filing on 2026‑09‑04

Background

Form 4 filings disclose insider transactions; investors monitor them for signals about management confidence.

Company-level read

Ticker impact

$KIDSBearishMedium confidence
Context

Squadron Capital LLC sold 22,500 shares of Orthopedics Corp (KIDS) for $525,375 in an open‑market sale filed on Form 4.

Expected impact

Potential slight downward pressure, likely limited to a few basis points.

Evidence & confidence

The sale represents a 0.35% reduction of holdings; market may view it as a minor bearish cue.

Market effects

Minimal impact on the orthopedics/medical device sector; no broader industry signal.

Limited to U.S. equity markets where KIDS trades.

Low; the transaction is company‑specific and does not affect global markets.

Counterpoint

The sale could be a routine portfolio rebalancing rather than a confidence issue.

Key entities

  • Squadron Capital LLC

    10% owner of Orthopedics Corp filing the sale.

  • Orthopedics Corp

    Medical device company listed on NASDAQ under ticker KIDS.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$KIDSMed

OrthoPediatrics Corp (KIDS) (Q3 2026) Earnings Call Highlights: Record Revenue and Raised Guidance

OrthoPediatrics Corp (KIDS) reported Q3 2026 revenue growth and raised guidance, despite increased sales expenses and gross margin pressure. The company expects Q4 revenue of roughly $69 million, with CEO David Bailey noting a conservative approach to guidance. International growth was tempered by Brazil headwinds, and the company remains unprofitable with a GAAP net loss per share of $0.25.

$KIDSMed

OrthoPediatrics Q3 Earnings Call Highlights

OrthoPediatrics (KIDS) reported Q3 revenue growth, with scoliosis revenue up 18% to $19.2M. The company surpassed 1,000 PNP tibial nail implantations and plans a full commercial release for PNP Retrograde in mid-2027. OPSB segment grew over 20%, with 60+ clinics. Gross margin remained at 74%, while GAAP net loss narrowed to $0.25 per share. The company raised full-year 2026 revenue guidance to $270M-$273M and expects positive free cash flow in 2027.

$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Q3 2026 Earnings Call Transcript

OrthoPediatrics (KIDS) reported Q3 2026 revenue of $727M, up 19% YoY, and raised full-year guidance to $270M-$273M. Growth was driven by legacy products, implant demand, and international sales. The company highlighted progress in its innovation super cycle, with new products like 3P Hip, Traxeo, and VerteGlide contributing to performance. Adjusted EBITDA and free cash flow were record highs, with plans to maintain positive cash flow in 2027.